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Background: To evaluate the risks and benefits of endoscopic submucosal dissection (ESD) in addition to
chemoradiotherapy (CRT) for the treatment of superficial esophageal squamous cell carcinoma (SESCC).
Methods and materials: We retrospectively reviewed the treatment outcomes of 47 patients with SESCC
treated between October 2000 and December 2011. Sixteen patients with invasion into the submucosal
layer (T1b) or the muscularis mucosa (m3) with positive vascular invasion were treated with CRT after ESD
(ESD-CRT group). The lymph node area was irradiated to a total dose of 40–44 Gy and a boost radiation
was administered if PET-positive lymph nodes or positive margins were observed. The remaining 31 patients
received definitive CRT only (dCRT group).
Results: The radiation field was significantly larger in the ESD-CRT group; the “long T” was used in 11 patients
(35.4%) in the dCRT group and 15 (93.7%) in the ESD-CRT group (p = 0.0001). The total radiation dose was
smaller in the ESD-CRT group; 40 Gy was used in 10 patients (62.5%) in the ESD-CRT group and all but one
patient in the dCRT group received ≥60 Gy (p = 0.00001). The 3-year overall survival rates in the dCRT and
ESD-CRT groups were 63.2% and 90.0% respectively (p = 0.118). Recurrence developed in nine patients (29.0%)
in the dCRT group and one (6.3%) in the ESD-CRT group. Local recurrence was observed in six patients (19%)
in the dCRT group and none in the ESD-CRT-group (p = 0.029). Pericardial effusion (≥Grade 3) occurred in
three patients (9.7%) in the dCRT group and none in the ESD-CRT group.
Conclusions: ESD followed by CRT is an effective and safe approach for SESCC at m3 or T1b. This combination of
ESD and CRT improves the local control rate, and it could decrease the number of cardiac toxicities due to a
radiation-dose reduction relative to CRT alone.
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Due to the development of endoscopic methods of diag-
nosis, the frequency of the detection of superficial esopha-
geal carcinoma has increased relative to the frequency of
the detection of esophageal squamous-cell carcinoma of
all stages [1]. Radical surgery with extended lymph node
dissection has been the main method used for treating
patients with clinical stage I esophageal cancer with sub-
mucosal invasion (T1b). Although the survival rate of
patients with submucosal tumors treated surgically at
3 years is over 80%, esophagectomy is highly invasive
and associated with increased morbidity and mortality
[2,3]. Definitive chemoradiotherapy (dCRT) has become
one of the less invasive alternative modalities [4]. Although
the overall survival afforded by dCRT is comparable that
of surgery, its higher risk of locoregional progression com-
pared to surgery remains a problem [5].
Endoscopic submucosal dissection (ESD) is an advanced
form of endoscopic mucosal resection (EMR) that enables
the removal of larger epithelial neoplasms in an en bloc
manner for complete resection, allowing detailed investi-
gations of the depth of invasion [6]. ESD is widely used to
treat superficial esophageal squamous cell carcinomas
(SESCCs) that are confined to the lamina propria mucosae
(T1a); however, the indications for ESD has expanded to
tumors that have invasion to muscularis mucosa (m3) or
submucosa (T1b) [7]. Despite the excellent local tumor
control after ESD, a potential shortcoming of ESD-alone
treatment for m3 or T1b tumors is its high accompanying
frequency of lymph node metastasis.
It is well known that if the invasion of a tumor is lim-
ited to the lamina propria mucosae (m2), the risk of
lymph node recurrence is extremely low. However, if the
tumor invades deeper than the muscularis mucosa or
pathology results show lymphovascular invasion, the rate
of subsequent lymph node recurrence jumps to 10%–50%
depending on the depth of invasion [8-10]. Therefore, ESD
alone cannot be considered curative. In order to prevent
locoregional progression after ESD for m3 or T1b tumors,
adjuvant chemoradiotherapy (CRT) might be effective.
Herein, we report the treatment outcomes from our initial
experience with this treatment approach.
Subjects and methods
The subjects were 47 consecutive patients with Stage I
(UICC 7th) primary SESCCs who underwent CRT in
our hospital between February 2000 and December
2011. Sixteen patients underwent CRT after ESD because
their pathology reports indicated invasion to the muscu-
laris mucosa (m3) or deeper (T1b) with or without lym-
phovascular invasion. These 16 patients constitute the
ESD-CRT group.
Six patients underwent dCRT only because ESD was not
available in our institution before 2003, and the remaining25 patients received dCRT only due to the suspicion of
submucosal invasion (T1b) or the massive degree of exten-
sion in the circumference or longitudinal direction on their
endoscopic ultrasound (EUS)-based diagnosis. These 31
patients constitute the dCRT-group. Written informed
consent to the treatment was obtained from all patients.
This study was approved by the Institutional Review Board
of Niigata University Hospital (IRB number 1881).
Chemoradiotherapy (CRT)
Radiation therapy planning was carried out with a com-
puted tomography (CT)-simulator and radiation treatment
planning system: the Eclipse ver. 8.9 (Varian Medical
Systems, Palo Alto, CA, USA) or the Focus ver. 3.0.0 or
XiO ver. 4.40 (Elekta, Stockholm, Sweden) or the Pinnacle
ver. 7.4 (Philips, Eindhoven, The Netherlands). Inhomo-
geneity correction was applied in all cases.
In the initial plan, the clinical target volume (CTV) in-
cluded the bilateral supraclavicular and the mediastinal
lymph nodes regions to bifurcation of the trachea for
cervical esophageal cancers, so called “Short T” field.
And the bilateral supraclavicular, all of the mediastinal,
the lesser curvature, and the celiac axis lymph nodes re-
gions were included for thoracic cancers, so called “Long
T” field. For the primary tumor sites in the boost plan,
the CTV margin was 2 cm in superior and inferior direc-
tions, and 0.5 cm in the other directions beyond the bor-
ders of the gross tumor volume (GTV). For the lymph
node metastasis, the CTV margin was 0.5 cm uniformly.
The planning target volume (PTV) was generated by using
1.0 to 1.5 cm expansion in superior and inferior direc-
tions, and 0.5 cm expansion in the other directions be-
yond the borders of the CTV in the initial and boost
plans. The prescription dose of the initial plan was 40 Gy
in 20 fractions except for one patient who received 44 Gy
in 22 fractions. The sites of positive margin in the ESD-
CRT group, primary tumor sites in the dCRT group, and
18-Fluoro-deoxyglucose positron emission tomography
(FDG-PET)-positive lymph nodes were irradiated to the
total dose of 60 to 66 Gy in the boost plans.
The regimen of chemotherapy was as follows: standard-
dose FP (CDDP 70 mg/m2, day 1, 5-FU 700 mg/m2 days
1–4, every 4 weeks) for patients <70 years old, Low-dose-
FP (CDDP 3–4 mg/m2 and 5-FU 200–250 mg/m2 for all
radiation treatment days) for patients aged 70–74 years,
and low-dose-5-FU (250 mg/m2 for all radiation treatment
days) for patients ≥75 years old. If the patient’s creatinine
clearance was less than 60 mL/min, nedaplatin was used
instead of CDDP.
Statistics
We analyzed the patients’ data regarding initial response,
pattern of recurrence, toxicities, and overall survival.
Toxicities were scored according to the National Cancer
Table 1 Background and treatments of the 47 patients
dCRT ESD-CRT p-value
Patients n = 31 n = 16
Age (median) 33–80 (68) 42–77 (65) 0.31
Gender (male:female) 25:6 15:1 0.229
Observation period (median) 2.5–93.1 (34.2) 6.5–78.4 (39.0) 0.682
Location 0.959
Cervical 2 0
Upper thoracic 1 1
Middle thoracic 18 10
Lower thoracic 10 5
Tumor depth
M3: 3 M3: 2 0.297
SM1: 15 SM1: 4
SM2: 13 SM2: 10
Radiation field
Long T 11 15 0.0001
Short T 3 1
Local 17 0
Radiation dose (Gy)





Standard-dose FP 12 10 0.046
Low-dose FP 6 4
Low-dose 5-FU 9 2
Others 4 0
Abbreviations: dCRT definitive chemoradiotherapy, ESD-CRT endoscopic
submucosal dissection + chemoradiotherapy.
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(NCI-CTCAE) version 4.0. Welch’s t-test was used for the
statistical analyses of age, observation period and radiation
dose. Fisher’s exact probability test was used for the
analyses of gender and adverse events. Mann-Whitney’s
U-test was used for the analyses of tumor location, tumor
depth, radiation field and chemotherapy. The survival
rates and the locoregional tumor control rate were exam-
ined using the Kaplan-Meier method, with statistical sig-
nificance assessed by the log-rank test. Survival rates were
calculated from the initiation of CRT. Any recurrence and
any death were counted as an event in the disease free
survival (DFS). Death owing to the esophageal cancer or
the adverse events was counted as an event in the cause-




The background and treatments of the dCRT and ESD-
CRT groups are summarized in Table 1. No significant
between-group difference was seen in the location of
tumor or the depth of invasion. With respect to the radi-
ation field, the long T was used in 11 patients (35.4%) in
the dCRT group and 15 (93.7%) in the ESD-CRT group
(p = 0.0001). The total dose was 40 Gy in 10 patients
(62.5%) in the ESD-CRT group. In contrast, all but one
of the 31 patients in the dCRT group received ≥60 Gy
(p = 0.00001).
Regarding the regimen of chemotherapy, the standard-
dose FP regimen was used significantly more frequently
in the ESD-CRT group (10/16, 62.5%) than in the dCRT
group (12/31, 38.7%) (p = 0.046). The observation period
was 2.5–93.1 mos (median 34.2 mos) in the dCRT group
and 6.5–78.4 mos (median 39.0 mos) in the ESD-CRT
group (p = 0.68).
Survival
For both groups combined, the 3-year overall survival
rate was 71.6% (95% confidence interval [CI] 57.2%–
86.1%). In the dCRT group, the 3-year overall survival
rate was 63.2% (95% CI 44.8%–81.6%), and that in the
ESD-CRT group was 90% (95% CI 71.4–100%) (p =
0.118) (Figure 1). The 3-year DFS rates were 63.1% (95%
CI 48.0%–78.2%) in both groups included, 54.2% (95%
CI 35.6%–72.8%) in the dCRT group and 82.1% (95% CI
59.1%–100%) in the ESD-CRT group (p = 0.116). The 3-
year CSS rates were 79.2% (95% CI 66.0%–92.3%) in
both groups included, 79.8% (95% CI 63.6%–96.1%) in
the dCRT group and 90% (95% CI 71.4%–100%) in the
ESD-CRT group (p = 0.578). The causes of death in the
dCRT group were attributed to primary cancer in three
patients, treatment-related adverse events in three,
and other causes in six. No patients in the ESD-CRTgroup died of cancer, and two patients died of myo-
cardial infarction.
Tumor control and pattern of recurrences
In the dCRT group, the initial tumor response was a
complete response (CR) in all but one patient, who
showed a partial response (PR). Tumor recurrence de-
veloped in nine patients (29.0%) in the dCRT group and
one patient (6.2%) in the ESD-CRT group. The pattern
of recurrence is summarized in Table 2. Local recur-
rence was predominant in the dCRT group (6/9, 66.7%),
whereas there were no case of local recurrence in the
ESD-CRT group (p = 0.029). Lymph node metastases out-
side of the radiation field developed in one patient in each
group. Distant metastases developed in 2 patients who
belonged to the dCRT group but none in the ESD-CRT
group. The 3-year locoregional tumor control rates of
80.1% (95% CI 67.5%–92.4%) for the combined groups,
Figure 1 The overall survival rates of the ESD-CRT (n = 16) and dCRT (n = 31) patients. ESD-CRT: endoscopic submucosal dissection +
chemoradiotherapy; dCRT: definitive chemoradiotherapy. The 3-year overall survival rate of the dCRT group (63.2%) was lower but not significantly
different (p = 0.118) from that of the ESD-CRT group (90.0%).









dCRT Local 6 mos Thoracic vertebrae No therapy Death from cancer
Low-dose FP 8.3 mos
dCRT Local 15.2 mos Local Argon plasma Death from cancer
Low-dose 5-FU Coagulation 34.2 mos
dCRT Local 8.7 mos Local Surgery Death from other cause
St-dose FP 18.1 mos
dCRT Long T 11.2 mos Local ESD No evidence of recurrence
Low-dose FP 85.9 mos
dCRT Local 11.2 mos LN Radiation Death from other cause
St-dose FP (Out of field) 19.3 mos
dCRT Long T 0 month Local ESD Treatment-related death
St-dose FP 28.2 mos
dCRT Short T 9.2 mos Local Surgery Death from other cause
St-dose FP 29.4 mos
dCRT Local 16.5 mos Local ESD Alive with cancer
Low-dose 5-FU 21.7 mos
dCRT Long T Unknown Carcinomatous No therapy Death from cancer
Low-dose 5-FU pericarditis 46.5 mos
ESD-CRT Long T 14.4 mos LN Surgery No evidence of recurrence
St-dose FP (Out of field) 68.9 mos
Abbreviations: ESD endoscopic submucosal dissection, FP 5-FU + CDDP, St-dose standard-dose, LN lymph node.
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Figure 2 Locoregional tumor control rates of the ESD-CRT and dCRT groups. The 3-year locoregional tumor control rates of the dCRT group
(73.3%) was lower but not significantly different from that of the ESD-CRT group (92.3%; p = 0.152).
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92.3% (95% CI: 77.8%–100%) in the ESD-CRT group (p =
0.152) (Figure 2).
Toxicities
The adverse events are summarized in Table 3. Radiation
pneumonitis (≥Grade 3) developed in two patients in the
dCRT group and none in the ESD-CRT group (p = 0.43).
Pericardial effusion (≥Grade 3) occurred in three pa-
tients in the dCRT group and none in the ESD-CRT
group (p = 0.277). Esophageal stricture (≥Grade 3) ap-
peared in one patient (3%) and four patients (25%) in
the dCRT and ESD-CRT groups, respectively (p = 0.040).Table 3 Adverse events* in the dCRT group and the ESD
+ CRT group
Adverse event ≥G3 dCRT ESD-CRT p-value
Leukopenia 13 (41.9%) 4 (25%) 0.206
Anemia 2 (6.5%) – 0.43
Thrombocytopenia 1 (3.2%) – 0.66
Esophagitis 3 (9.7%) 2 (12.5%) 0.264
Nausea 1 (3.2%) 3 (18.8%) 0.108
Pneumonia 2 (6.5%) – 0.43
Grade 5: 1
Gastric ulcer 1 (3.2%) – 0.66
Grade 5: 1
Esophageal stenosis 1 (3.2%) 4 (25%) 0.04
Pericardial effusion 3 (9.7%) – 0.277
Grade 5: 1
Myocardial infarction – Grade5: 2 0.111
Total of grade 5 3 2 0.42
*Adverse events ≥ G3 in NCI-CTCAE ver.4.0.Discussion
Definitive CRT has become one of the less invasive treat-
ment options compared to surgery for SESCC. In a Japanese
Phase II trial (JCOG9708), it was found that the survival
after dCRT was comparable to survival following sur-
gery in stage I disease, with a 4-year survival rate of
80.5% [4]. However, 21 of 72 patients showed local
relapses that needed salvage treatment. Yamamoto et al.
retrospectively compared treatment outcomes between
dCRT and esophagectomy in patients with clinical stage I
esophageal squamous cell carcinoma. Although the overall
survival of the dCRT group was comparable with the haz-
ard ratio of 0.95, the incidence of local recurrence in
the dCRT group was significantly higher than that in
the esophagectomy group (p < 0.0001) [11]. Therefore the
local tumor control remains the biggest problem of the
dCRT.
A potential solution could be the use of EMR or ESD
before CRT [12,13]. The local control rates of ESD are
reported to be over 95% [7], although the frequency of
lymph node metastases is not negligible for m3 and T1b
cases. Therefore, the combination therapy of ESD and
CRT might offset their shortcomings and be less invasive
than a surgical approach. Shimizu et al. reported that
after EMR combined with CRT to a total dose of 40 to
46 Gy for 16 patients with SESCCs invading the muscu-
laris mucosa or upper submucosa, no local or distant
metastasis was observed [13].
In the present study, no local tumor recurrence or in-
field lymph node recurrence occurred among the pa-
tients who underwent CRT of 40 Gy in 20 fractions after
ESD for m3 or T1b SESCCs. The tumor recurrence was
significantly less frequent in the ESD-CRT group (6.2%,
1/16) than in the dCRT group (29.0%, 9/31). Especially,
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compared to 19.3% (6/31) in the dCRT group.
In regard to the toxicities, it is noteworthy that symp-
tomatic radiation-induced pericardial effusion (PCE) de-
veloped only in patients in the dCRT group (9.7%). PCE
is not unusual and is potentially life-threatening, hence
this is one of the most important toxicities. Wei et al. re-
ported that when V30 of the pericardium was greater than
46% versus less than or equal to 46%, the rate of PCE at
18 mos post-therapy was 73% versus 13%, respectively
(p = 0.001) [14]. Martel et al. demonstrated that both
an average dose > 27.1 Gy (p = 0.014) and a maximum
dose > 47.0 Gy (p = 0.014) have a significant relationship
with the incidence of PCE [15]. Fukada et al. reported that
the incidence of symptomatic PCE was significantly higher
in the patients who received a mean pericardial dose
exceeding 36.5 Gy (p < 0.0001) [16]. In the present study,
a significant dose reduction could be achieved in the
ESD-CRT group compared to the dCRT group, although
the treatment field was significantly larger. The decrease
of the rate of PCE in our ESD-CRT group compared to
the dCRT group would thus be explained by the dose re-
duction achieved in the ESD-CRT group. Regarding the
esophageal stricture, it appeared in four patients (25%) in
the ESD-CRT groups. However, three of four patients had
a stricture under the influence of ESD before CRT and did
not worsen after CRT.
The present study has several limitations. The study de-
sign was not a randomized assignment, the sample size
was small, and the treatment indications for the dCRT
group were different from those of the ESD-CRT group.
The difference in indications between the two treatments
might have affected the local control rate in that the out-
come of the dCRT group was worse than that of the
ESD-CRT group, but in-field lymph node recurrences
were prevented well in both groups.
Conclusions
Our results suggest that CRT after ESD is an effective
and safe approach for patients with SESCC invading the
m3 or T1b. If the patient’s case meets the indications for
ESD, this combination treatment should be actively con-
sidered because performing ESD before CRT improves
the local control rate, and doing so can decrease the num-
ber of cardiac toxicities due to a radiation-dose reduction
relative to CRT alone.
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